Closing the diversity gap in genomics
In this article, Drug Target Review’s Ria Kakkad explores the importance of diverse and inclusive samples in genomic studies with Assistant Professor Lindsay Fernández-Rhodes, Pennsylvania State University.
List view / Grid view
In this article, Drug Target Review’s Ria Kakkad explores the importance of diverse and inclusive samples in genomic studies with Assistant Professor Lindsay Fernández-Rhodes, Pennsylvania State University.
Scientists at the Endocrine Society have found extracellular vesicles may offer new insights into treating endocrine disorders.
A new study by University of Texas Health Science Center at San Antonio has found that boosting liver mRNAs in obese mice reduces appetite and body weight.
Researchers from the University of Pennsylvania may have discovered how to eliminate the risk of weight gain from certain diabetes medications by uncovering the difference between two varieties of a protein.
The study uncovered disordered signalling in the brain's cerebellum, offering a novel therapeutic target for Prader Willi syndrome.
Researchers used obese fruit flies to analyse how gene activities affect triacylglyceride levels, unveiling novel drug targets for obesity.
Treatment with Viking Therapeutics' dual agonists resulted in mean reductions in body weight of up to 27 percent compared to semaglutide-treated animals.
Scientists have discovered a new pharmacological approach to reduce the mitochondrial dysfunction that promotes diet-induced obesity in mice.
Researchers have revealed that the immune system of obese mice treated with TSLP released lipids through sebaceous glands.
A synthetically made glycopeptide biologic has shown promise as a treatment for obesity-related diseases in mice.
Researchers have shown that loss of Asc-1 function could help obese patients maintain a healthy metabolism.
Researchers have shown that a GLP-1/GIP dual-agonist targets the GIP receptor in the brain and CNS to reduce body weight and food intake.
New research has provided a metabolic atlas for insights into obesity and tumours' ability to hide from the immune system.
Recent reports suggest that both clinical and genetic risk factors may contribute to COVID-19 susceptibility and severity. Catherine Ball, Chief Scientific Officer of Ancestry®, discusses results of the company’s COVID-19 Research Study, designed to explore non-genetic and genetic associations with disease outcomes.
Researchers have found that the PI3K signalling pathway could be targeted to prevent liptoxicity and combat obesity.